THE EEU SCIENTIFIC MODEL:
Common Questions & Answers
The EEU model has attracted significant attention from the scientific community and leaders in the field of allergy, and generated a number of common questions as one might anticipate with the development of a new methodology to study allergic rhinitis.
The concerns that have been raised during discussions about the EEU are critically reviewed along with evidence from studies undertaken to address these questions.
Does the EEU represent 'real life' conditions experienced by patients?
What is the advantage of circulating only a single test-allergen in the EEU?
What is "priming"? Why "prime" study participants in the EEU?
What determines the allergen concentration used in an EEU study?
Does the subject interaction in the EEU have any influence on study results? Can subjects distinguish efficacy and dose in the EEU?
Are there any limitations on who can participate in EEU studies? Who makes up an EEU study population?
Are all EEU studies of short duration? Can longer studies be undertaken in the EEU?
Is there less experience with the EEU model than other methods?
